DK0497915T3 - hPTH-fragment(1-37), fremstilling heraf, lægemiddel, som indeholder det, samt anvendelse heraf - Google Patents

hPTH-fragment(1-37), fremstilling heraf, lægemiddel, som indeholder det, samt anvendelse heraf

Info

Publication number
DK0497915T3
DK0497915T3 DK90917747.9T DK90917747T DK0497915T3 DK 0497915 T3 DK0497915 T3 DK 0497915T3 DK 90917747 T DK90917747 T DK 90917747T DK 0497915 T3 DK0497915 T3 DK 0497915T3
Authority
DK
Denmark
Prior art keywords
hpth
fragment
peptide
existence
fragments
Prior art date
Application number
DK90917747.9T
Other languages
Danish (da)
English (en)
Inventor
Wolf-Georg Forssmann
Franz Herbst
Peter Schulz-Knappe
Knut Adermann
Michael Gagelmann
Original Assignee
Haemopep Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemopep Pharma Gmbh filed Critical Haemopep Pharma Gmbh
Application granted granted Critical
Publication of DK0497915T3 publication Critical patent/DK0497915T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DK90917747.9T 1989-10-27 1990-10-25 hPTH-fragment(1-37), fremstilling heraf, lægemiddel, som indeholder det, samt anvendelse heraf DK0497915T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3935738A DE3935738A1 (de) 1989-10-27 1989-10-27 Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff

Publications (1)

Publication Number Publication Date
DK0497915T3 true DK0497915T3 (da) 1995-09-25

Family

ID=6392300

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90917747.9T DK0497915T3 (da) 1989-10-27 1990-10-25 hPTH-fragment(1-37), fremstilling heraf, lægemiddel, som indeholder det, samt anvendelse heraf

Country Status (10)

Country Link
EP (1) EP0497915B1 (fr)
JP (1) JP3135122B2 (fr)
AT (1) ATE121424T1 (fr)
AU (1) AU643725B2 (fr)
CA (1) CA2071538C (fr)
DE (2) DE3935738A1 (fr)
DK (1) DK0497915T3 (fr)
ES (1) ES2071837T3 (fr)
GR (1) GR3015909T3 (fr)
WO (1) WO1991006564A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
DE4203040A1 (de) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE4434551A1 (de) * 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
DE19517430A1 (de) * 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
JP2000500019A (ja) * 1995-11-16 2000-01-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ストレプトアビジン融合タンパク質経由でのペプチドの生産方法
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA988030B (en) * 1997-09-09 1999-03-09 Hoffmann La Roche Fracture healing using pthrp analogs
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US7893021B2 (en) 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
WO2015025335A1 (fr) * 2013-08-21 2015-02-26 Cadila Healthcare Limited Procédé de purification de pth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology

Also Published As

Publication number Publication date
JPH05505594A (ja) 1993-08-19
JP3135122B2 (ja) 2001-02-13
AU6871291A (en) 1991-05-31
AU643725B2 (en) 1993-11-25
ES2071837T3 (es) 1995-07-01
CA2071538C (fr) 2000-09-19
EP0497915A1 (fr) 1992-08-12
GR3015909T3 (en) 1995-07-31
DE3935738A1 (de) 1991-05-08
CA2071538A1 (fr) 1991-04-28
WO1991006564A1 (fr) 1991-05-16
ATE121424T1 (de) 1995-05-15
DE59008949D1 (de) 1995-05-24
EP0497915B1 (fr) 1995-04-19

Similar Documents

Publication Publication Date Title
DK0497915T3 (da) hPTH-fragment(1-37), fremstilling heraf, lægemiddel, som indeholder det, samt anvendelse heraf
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
GB2108388A (en) Composition and method for treating alcohol and drug addicts
EP0526544A4 (en) Therapeutic uses of actin-binding compounds
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
DE69032484T2 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GR1001065B (el) Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων.
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
Mason et al. Blood concentrations of dihydroxylated vitamin D metabolites after an oral dose.
GREGERSEN Postpartum haemolytic-uraemic syndrome successfully treated with antithrombin III
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
Biggs et al. Prolonged Q fever associated with inappropriate secretion of anti-diuretic hormone
Gordan A direct action of parathyroid hormone on dead bone in vitro
HUT41632A (en) Process for preparing agents for the enhancement of protein absorption
Kotkes et al. New approaches to the characterization and isolation of migration inhibitory factor (MIF)
DK0489771T3 (da) Modificerede humane anti-Rh(D)-antistoffer
AU5125001A (en) Neutralizing immunogenic hev polypeptides
JPS6490127A (en) Method for remedying malignant tumor or such and composition for remedying same
ES2015772A6 (es) Procedimiento e obtencion de nuevos derivados del 5-fluorouracilo, concretamente los n1-acil-sustituidos-n3-orto-toluil-5-fluorouracilo.
ECSP982660A (es) USO DE ANALOGOS DEL PTHrP EN LA CICATRIZACION DE FRACTURAS
BG49634A1 (en) Method for prepraing of thioreotropen hormone